RUNX1 dosage in development and cancer

Lie-A-Ling, M., Mevel, R., Patel, R., Blyth, K. , Baena, E., Kouskoff, V. and Lacaud, G. (2020) RUNX1 dosage in development and cancer. Molecules and Cells, 43(2), pp. 126-138. (doi: 10.14348/molcells.2019.0301) (PMID:31991535) (PMCID:PMC7057845)

Abstract

The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Blyth, Professor Karen
• Authors: Lie-A-Ling, M., Mevel, R., Patel, R., Blyth, K., Baena, E., Kouskoff, V., and Lacaud, G.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Molecules and Cells
• Publisher: Korean Society for Molecular and Cellular Biology
• ISSN: 1016-8478
• ISSN (Online): 0219-1032
• Published Online: 24 January 2020
• Copyright Holders: Copyright © 2020 Korean Society for Molecular and Cellular Biology
• First Published: First published in Molecules and Cells 43(2): 126-138
• Publisher Policy: Reproduced under a Creative Commons License